SCHEMBL2747656

SCHEMBL2747656

COC/C=C/c1cc(C(C)(C)C)ccc1S(=O)(=O)Nc1ccsc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.45
PARP14 Q460N5 1/20 0.44
KCNH2 Q12809 1/20 0.43
METAP2 P50579 6/20 0.42
KDM4E B2RXH2 1/20 0.41
CCR9 P51686 2/20 0.40
SLC10A6 Q3KNW5 1/20 0.38
TSHR P16473 2/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
MEN1 O00255 1/20 0.34
CYP3A4 P08684 1/20 0.34
KMT2A Q03164 1/20 0.34
WDR5 P61964 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747659 1.00 ACLY (0.45) ACLYPARP14KCNH2METAP2KDM4E
SCHEMBL2750111 0.92 KCNH2 (0.53) PARP14KCNH2METAP2CCR9SLC10A6
SCHEMBL2750113 0.92 KCNH2 (0.53) PARP14KCNH2METAP2CCR9SLC10A6
SCHEMBL2749339 0.86 ACLY (0.47) ACLYPARP14KCNH2METAP2KDM4E
SCHEMBL2749338 0.86 ACLY (0.47) ACLYPARP14KCNH2METAP2KDM4E
SCHEMBL2747304 0.85 ACLY (0.46) ACLYPARP14KCNH2KDM4ECCR9
SCHEMBL2748528 0.85 ACLY (0.46) ACLYPARP14KCNH2KDM4ECCR9
SCHEMBL2748718 0.83 ACLY (0.45) ACLYPARP14KCNH2KDM4ECCR9
SCHEMBL2750468 0.83 ACLY (0.45) ACLYPARP14KCNH2KDM4ECCR9
SCHEMBL2748727 0.83 ACLY (0.48) ACLYPARP14KCNH2KDM4ECCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF CCR9, CCR1, CCR4 ACLY 4546/4885PARP14 2997/4885KCNH2 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.